1. Meaning of research funding

Research funding means financial or material support provided for conducting research.

Funding can come from:

• Central or State Governments;
• ICMR;
• Department of Health Research;
• Department of Biotechnology;
• universities;
• public research institutions;
• international organisations;
• charitable foundations;
• pharmaceutical companies;
• biotechnology companies;
• medical-device companies;
• hospitals; or
• private sponsors.

Funding can include more than direct cash.

It may include:

• salaries;
• research grants;
• equipment;
• laboratory facilities;
• travel support;
• consultancy payments;
• investigator fees;
• data-management support;
• study drugs/devices;
• statistical support; and
• publication-related support.

The legal/ethical problem arises when the source of funding creates an incentive to produce a particular research result.

2. Meaning of conflict of interest

The ICMR defines Conflict of Interest as a situation in which professional judgment concerning a primary interest—such as participant welfare or validity of research—tends to be, or appears to be, unduly influenced by a secondary interest, including financial or non-financial interests.

Thus, COI does not necessarily mean that the researcher has actually acted dishonestly.

There are three important categories.

Actual conflict

The researcher's financial interest actually affects professional judgment.

Potential conflict

Circumstances exist in which the financial/personal interest could influence future judgment.

Perceived/apparent conflict

Even if the researcher is completely objective, a reasonable observer could question the researcher's independence.

The third category is important because public confidence in research is itself an ethical value.

3. Why funding creates a conflict of interest

Consider this example:

A pharmaceutical company is developing Drug X.

It pays ₹50 lakh to a research institution to conduct a clinical trial.

The principal investigator:

• receives consultancy fees from the company;
• owns shares in the company; or
• expects future research funding from the company.

The researcher may consciously remain objective.

Nevertheless, there is a legitimate concern:

Could the financial relationship influence patient recruitment, statistical analysis, interpretation of adverse events or publication of results?

That is why disclosure and management, rather than merely proving actual bias after the event, are central to research ethics.

4. Constitutional basis

Although the Constitution does not contain a provision specifically titled "research funding disclosure", several constitutional principles are relevant.

Article 14 — Equality and non-arbitrariness

Government-funded research and regulatory decision-making must be transparent and non-arbitrary.

Article 19(1)(a) — Freedom of speech and expression

This can become relevant to:

• publication of research results;
• academic freedom;
• dissemination of scientific findings; and
• restrictions on publication.

Article 21 — Life, health and bodily integrity

Article 21 becomes especially important when research involves human participants.

Clinical research that exposes participants to risk must satisfy requirements of:

• informed consent;
• safety;
• scientific validity;
• ethics review;
• compensation where applicable; and
• transparency.

Thus, financial interests cannot override the participant's right to safety and dignity.

5. ICMR National Ethical Guidelines

The principal ethical framework is the ICMR National Ethical Guidelines for Biomedical and Health Research involving Human Participants.

The ICMR's current guidelines portal lists the 2017 National Ethical Guidelines and subsequent additions/updates.

The guidelines expressly deal with:

• responsible conduct of research;
• research funding;
• conflicts of interest;
• ethics committees;
• data ownership;
• publication;
• scientific integrity;
• informed consent; and
• relationships between researchers and commercial sponsors.

6. Disclosure of research funding

One of the most important requirements is that the source and amount of industry funding should be disclosed.

The ICMR ethical framework states that investigators should declare conflicts of interest to the Institutional Ethics Committee and that research participants should be informed about the sponsorship of research. Financial secondary interests should also be disclosed to relevant audiences and in scientific publications.

The ethical framework therefore operates at several levels:

Level 1 — Ethics Committee

The investigator must disclose relevant interests to the IEC.

Level 2 — Research participant

The participant should know about relevant research sponsorship where it may affect the ethical assessment of the research.

Level 3 — Scientific publication

Funding and relevant conflicts should be disclosed in publications.

Level 4 — Public transparency

For industry-funded medical research, the source and amount of funding should be publicly disclosed at the outset.

7. Industry-funded medical research

Industry funding is not prohibited.

This is an important distinction.

A pharmaceutical company can legitimately fund:

• clinical trials;
• observational studies;
• laboratory research;
• epidemiological research;
• drug-development research; and
• medical-device research.

The problem is not who pays.

The problem is whether the funding relationship compromises:

• scientific independence;
• participant safety;
• data integrity;
• publication freedom;
• informed consent; or
• public trust.

The ICMR guidelines recognise that academic institutions may conduct research in collaboration with commercial companies, but require systems for identifying and managing conflicts.

8. Funding must go through appropriate institutional channels

A particularly important principle concerns direct personal payments.

The professional-ethics framework applicable to medical practitioners provides that research funding from pharmaceutical/allied healthcare industries should be received through approved institutions, according to applicable law/rules/guidelines, in a transparent manner and with full disclosure.

Thus, there is an important distinction between:

Legitimate institutional research grant

Pharmaceutical company → University/hospital/research institution → approved research project

and

Problematic personal payment

Pharmaceutical company → researcher's private account → researcher's discretionary use

The second arrangement creates a much greater risk of:

• undisclosed financial interest;
• personal inducement;
• manipulation of research;
• tax/accounting irregularity; and
• professional misconduct.

9. Conflict of interest in the ICMR framework

The ICMR guidelines identify significant financial interests such as:

• salary;
• consultancy fees;
• honoraria;
• payments per participant;
• equity interests;
• stock options;
• ownership interests;
• patents; and
• royalties. 

Therefore, a conflict is not limited to receiving a research grant.

A researcher can have a COI because of:

salary + consultancy + shareholding + patent + royalty + personal relationship + academic interest

depending upon the circumstances.

10. Example: patent-related conflict

Suppose Professor A invents a medical device.

Professor A owns the patent.

Professor A then conducts a clinical study demonstrating that the device is highly effective.

Even if the study is scientifically sound, Professor A has a significant financial interest in the result.

Why?

Because:

Positive research result → increased value/commercial success of device → increased value of Professor A's patent/business.

This should therefore be disclosed.

11. Conflict of commitment

COI is broader than money.

The ICMR framework also recognises issues concerning conflict of commitment.

For example:

A researcher has:

• a university appointment;
• a consultancy with a pharmaceutical company; and
• responsibilities under a commercial research project.

If the commercial work substantially interferes with the researcher's institutional responsibilities, another form of conflict can arise.

Therefore, research ethics considers both:

Conflict of Interest

and

Conflict of Commitment.

12. Institutional Ethics Committee

The Institutional Ethics Committee (IEC) is one of the principal safeguards.

An IEC must consider whether a research project is ethically acceptable.

The ICMR guidelines specifically require Ethics Committees to:

• evaluate disclosed conflicts;
• ensure appropriate action to mitigate them;
• require their own members to disclose conflicts; and
• require members with conflicts to recuse themselves from review or decision-making. 

This is crucial.

Example

Suppose an Ethics Committee member owns shares in the company sponsoring a clinical trial.

That member should not participate in the Committee's decision on that trial.

Otherwise, the review process itself becomes conflicted.

13. Conflict disclosure by Ethics Committee members

COI is therefore a two-sided obligation.

Researcher must disclose

The investigator must disclose relevant financial/personal interests.

Ethics Committee member must disclose

The reviewer must disclose conflicts relating to the protocol.

Institutional management

The institution must have mechanisms to:

• identify;
• record;
• manage;
• mitigate; and
• monitor conflicts.

This ensures that the Ethics Committee is not merely a formal approval body.

14. Clinical trials and financial incentives

The Supreme Court has directly considered the relationship between clinical-trial funding and investigator incentives.

Swasthya Adhikar Manch v. Union of India

This is one of the most important cases.

Citation

Swasthya Adhikar Manch, Indore v. Ministry of Health & Family Welfare, (2014) 11 SCC 257.

The case concerned regulation of clinical trials in India.

The Supreme Court recognised that clinical trials are necessary for development of new drugs but emphasised the need for a robust regulatory system ensuring that trials are scientifically and ethically conducted.

15. Supreme Court on payment to investigators

One of the most significant observations in Swasthya Adhikar Manch concerned payments made by sponsors to investigators.

The Court recognised that:

money paid by sponsors/companies to investigators may act as an inducement to conduct clinical trials.

The Court specifically noted the possibility that such inducement could influence enrolment of trial subjects and recommended regulatory mechanisms to ensure that information about amounts paid by companies to investigators was known to regulatory authorities.

Importance

This establishes a direct judicial connection between:

Research funding → financial incentive → investigator behaviour → participant protection.

That is one of the most important propositions for an examination answer.

16. Supreme Court's broader approach in Swasthya Adhikar Manch

The Court did not say:

“Commercially funded clinical trials are unlawful.”

Instead, it recognised that clinical trials are necessary but must be governed by a robust regulatory system.

The Court emphasised:

• scientific validity;
• ethical conduct;
• informed consent;
• participant safety;
• compensation;
• regulatory supervision; and
• transparency.

Thus, the correct legal approach is:

Permitted funding + controlled conflict + independent ethical review + transparency.

17. Jacob Puliyel v. Union of India

Another useful case is:

Jacob Puliyel v. Union of India, 2022 SCC OnLine SC 533.

The Supreme Court considered issues concerning transparency, scientific evidence and COVID-19 vaccine-related regulatory matters.

The judgment referred to principles requiring accountability and transparency, including disclosure by those associated with a study of their interests and conflicts of interest.

The Court also referred to principles of making research and its results available in the public domain, subject to legitimate privacy, confidentiality and intellectual-property considerations.

Importance

This case reinforces the broader principle that scientific research affecting public health cannot be treated as an entirely private matter.

Where public health is implicated:

Transparency and disclosure become particularly important.

18. Vascular Concepts Ltd. v. DCIT

A useful Indian decision concerning medical-research funding is:

M/s Vascular Concepts Ltd. v. DCIT (Central Circle-1(4), Bangalore).

The Income Tax Appellate Tribunal discussed professional/ethical requirements relating to industry-funded medical research.

It recorded the principle that funding for medical research should be received through approved institutions, according to applicable rules/guidelines, transparently and with full disclosure.

The Tribunal also referred to requirements including:

• competent-authority permission;
• Ethics Committee clearance;
• compliance with legal requirements;
• public disclosure of source and amount of funding;
• protection of human volunteers; and
• freedom to publish results in the broader public interest. 

Caveat

This is an ITAT decision, not a Supreme Court constitutional precedent. It is therefore best used as persuasive/application-level authority rather than as the principal source of the legal rule.

19. Aristo Pharmaceuticals case

In DCIT v. Aristo Pharmaceuticals Pvt. Ltd., the Income Tax Appellate Tribunal also discussed professional requirements concerning pharmaceutical-industry-funded research.

The decision referred to the requirement that:

• funding source and amount be publicly disclosed;
• human volunteers receive appropriate care;
• the researcher maintain professional autonomy; and
• the investigator retain freedom to publish research results. 

Again, this decision is useful for demonstrating how Indian regulatory/professional norms treat industry-funded medical research, although it should not be presented as equivalent to a Supreme Court judgment.

20. Freedom to publish research results

One of the most important safeguards against sponsor influence is publication independence.

Suppose a company funds a clinical trial.

The company obtains a contract saying:

“The researcher cannot publish negative results without the company's permission.”

This creates a serious conflict.

Why?

Because the sponsor could suppress:

• adverse results;
• evidence of ineffectiveness;
• safety concerns; or
• statistically insignificant findings.

The ethical framework therefore stresses the researcher's ability to publish results in the broader public interest.

The professional-ethics provisions referred to in Indian tax jurisprudence specifically require that an industry-funded medical researcher retain freedom to publish research results.

21. Selective publication

A particularly serious form of research bias is selective publication.

Suppose:

Study 1

Drug works very well → published.

Study 2

Drug does not work → suppressed.

Study 3

Drug causes serious adverse effects → not published.

The scientific literature would create the false impression that the drug is highly effective.

Therefore, transparency in funding must be accompanied by:

• trial registration;
• publication of results;
• disclosure of conflicts; and
• preservation of research data.

22. Clinical Trial Registry–India

Clinical-trial registration is an important transparency mechanism.

Clinical trials conducted in India are expected to be registered in the Clinical Trials Registry–India (CTRI) in accordance with the applicable regulatory/ethical framework.

Registration helps create a public record concerning:

• trial sponsor;
• investigator;
• study design;
• objectives;
• intervention;
• outcomes; and
• other important trial characteristics.

This makes it more difficult to secretly conduct a trial and later report only favourable results.

23. Drugs and Clinical Trials Rules, 2019

For clinical trials involving new drugs and related regulatory activities, the New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019) are important.

The Rules provide the regulatory structure for:

• clinical trials;
• ethics committees;
• new-drug approval;
• academic clinical trials;
• compensation for trial-related injury/death;
• regulatory oversight; and
• related procedures.

Therefore, a research-funding question involving a pharmaceutical clinical trial should not be answered only by referring to the ICMR guidelines.

The analysis should consider:

D&C Act + NDCTR 2019 + ICMR ethical guidelines + Ethics Committee requirements + CTRI + professional regulations.

24. National Health Research Policy 2026

There is also an important contemporary development.

India's National Health Research Policy 2026 expressly provides that institutions and national bodies should establish clear protocols for the:

• identification;
• disclosure; and
• management

of conflicts of interest in:

• research;
• review; and
• funding decisions. 

The Policy also requires biomedical and health research to comply with ICMR ethical guidelines and applicable legal/regulatory requirements and requires appropriate ethics review before research requiring ethical review begins.

This strengthens the argument that COI is not merely a matter of individual professional morality—it is increasingly part of institutional research governance.

25. Funding disclosure versus conflict disclosure

These concepts should not be confused.

Example

A study may state:

“This study was funded by ABC Pharmaceuticals.”

That is funding disclosure.

But the principal investigator may also need to state:

“The investigator has received consultancy fees from ABC Pharmaceuticals and holds an equity interest.”

That is COI disclosure.

Both may be necessary.

26. Financial versus non-financial conflicts

COI is not restricted to money.

Financial

• consultancy;
• shares;
• stock options;
• patents;
• royalties;
• research grants;
• speaker fees;
• honoraria.

Academic

A researcher may strongly want a particular theory to succeed because it could establish their academic reputation.

Personal

A researcher could have a close relationship with the sponsor or participant.

Institutional

A university may have a financial relationship with the company sponsoring the research.

Political/social

Research may affect a researcher's public position or advocacy interests.

The ICMR framework expressly recognises both financial and non-financial secondary interests.

27. Undue inducement

There is a major difference between:

reasonable research funding/participant reimbursement

and

undue inducement.

Participants may legitimately receive reimbursement for:

• travel;
• meals;
• loss of wages;
• expenses;
• research-related costs.

But compensation should not be so excessive that it causes a person to ignore significant risks merely because of the money.

The ICMR guidelines expressly state that undue inducement through compensation should be prohibited, while recognising legitimate arrangements such as travel reimbursement, loss of wages, healthcare reimbursement and certain benefit-sharing arrangements.

28. Funding and informed consent

Funding arrangements can be relevant to informed consent.

A participant should not be misled into believing that:

“This is purely government research”

when it is actually sponsored by a pharmaceutical company.

Where sponsorship is ethically relevant, participants should be appropriately informed.

The ICMR guidelines specifically state that prospective participants should be informed about research sponsorship so that they understand potential conflicts and commercial aspects of research.

29. Ethics Committee management of COI

The Ethics Committee can use several methods to manage COI.

1. Disclosure

Require the investigator to formally declare the interest.

2. Recusal

Require conflicted Committee members to leave the discussion/decision.

3. Independent statistical analysis

Where appropriate, an independent statistician can analyse data.

4. Independent monitoring

An independent monitoring body may be used.

5. Modification of funding arrangement

The sponsor may be prevented from controlling data analysis.

6. Publication safeguards

The investigator may be required to retain publication rights.

7. Disclosure in publications

The conflict must be disclosed to readers.

8. Removal from research

In serious cases, the researcher may be prohibited from participating.

30. Data ownership and funding

Funding raises another important issue:

Who owns the research data?

The ICMR guidelines state that institutions receiving research funds have responsibilities concerning:

• budgets;
• regulatory compliance;
• management of collected data; and
• clarity regarding data ownership and publication rights.

They also recommend institutional arrangements/MoUs dealing with these matters before data collection.

Therefore, a funding agreement should clearly address:

• data ownership;
• access;
• analysis;
• publication;
• confidentiality;
• intellectual property;
• storage;
• destruction;
• secondary research; and
• regulatory inspection.

31. Intellectual property and conflict

Suppose a university researcher develops a patented drug or device during a sponsored project.

There can be overlapping interests:

Researcher → wants publication

University → wants patent protection

Company → wants commercial secrecy

Public → needs access to safety/effectiveness information

The funding agreement must therefore balance:

• IP rights;
• academic publication;
• confidentiality; and
• public-health transparency.

A sponsor should not ordinarily be permitted to suppress safety information merely by invoking commercial confidentiality.

32. Research misconduct and funding

Funding-related misconduct may include:

• falsifying funding information;
• hiding sponsor relationships;
• fabricating data;
• manipulating statistical analysis;
• suppressing adverse results;
• duplicate publication;
• plagiarism;
• falsifying ethics approval;
• enrolling participants without proper approval; or
• misusing grant money.

The ICMR Policy on Research Integrity and Publication Ethics (RIPE) is part of India's research-integrity framework.

Thus:

Undisclosed funding can be a COI issue; manipulated research can become research misconduct; misuse of grant money can additionally raise financial/legal issues.

33. Role of institutions

Research institutions have significant responsibilities.

They should establish:

• COI policies;
• grant-management systems;
• ethics-review procedures;
• disclosure forms;
• audit mechanisms;
• data-management policies;
• publication policies;
• conflict-resolution mechanisms; and
• sanctions for misconduct.

The ICMR guidelines specifically recognise institutional responsibilities concerning funding, budgets, regulatory compliance and data management.

34. Role of the Ethics Committee

An Ethics Committee should ask questions such as:

1. Who is funding the research?
2. How much funding is being provided?
3. Who will receive the money?
4. Is the investigator receiving personal compensation?
5. Does the investigator hold shares in the sponsor?
6. Does the investigator own relevant patents?
7. Does the sponsor control the data?
8. Can the investigator publish negative findings?
9. Are participants being adequately informed?
10. Is participant compensation reasonable?
11. Is there independent monitoring?
12. What happens if the investigator's conflict becomes serious during the study?

This demonstrates why COI disclosure must happen before research begins.

35. A hypothetical example

Suppose Pharma Company A funds a ₹2 crore clinical trial at Hospital B.

The principal investigator receives:

• ₹20 lakh consultancy fees;
• ₹10 lakh research honorarium;
• shares in Pharma Company A; and
• future research funding commitments.

The investigator then concludes that Drug X is completely safe.

Legal/ethical analysis

There is no automatic presumption that the conclusion is false.

However, there are substantial COIs.

The researcher should disclose:

• sponsorship;
• funding amount where required;
• consultancy;
• equity;
• other significant financial interests.

The Ethics Committee should assess whether mitigation is necessary.

Potential safeguards could include:

• independent statistical analysis;
• independent safety monitoring;
• recusal from certain decisions;
• publication protections; and
• disclosure in the final publication.

36. Case law — consolidated analysis

A. Swasthya Adhikar Manch v. Union of India

(2014) 11 SCC 257

Key principle

Commercial funding of clinical trials can create incentives affecting investigator behaviour.

The Supreme Court specifically recognised that sponsor payments to investigators could operate as inducements and recommended regulatory awareness of the amounts paid.

Importance

This is the strongest Supreme Court authority for linking research funding with conflict-of-interest concerns.

B. Jacob Puliyel v. Union of India

2022

Key principle

The judgment emphasised principles of accountability and transparency, including disclosure of interests and conflicts associated with research and making research information available in the public domain, subject to legitimate confidentiality/privacy considerations.

Importance

Useful for establishing the broader principle of transparency in public-health research.

C. Vascular Concepts Ltd. v. DCIT

ITAT Bangalore, 29 January 2018

Key principle

The decision discussed the requirement that medical research funding be received through appropriate institutions, transparently and with disclosure. It also referred to Ethics Committee approval, public disclosure of the source and amount of funding, and freedom to publish results.

Importance

Useful as supplementary authority concerning industry-funded medical research.

D. DCIT v. Aristo Pharmaceuticals Pvt. Ltd.

ITAT, 26 July 2018

Key principle

The Tribunal referred to professional requirements concerning:

• disclosure of funding source and amount;
• care of human volunteers;
• professional autonomy; and
• freedom to publish research findings. 

Importance

Again, this is supplementary rather than a Supreme Court constitutional precedent.

37. Current legal/ethical framework — simplified

A biomedical research project in India may therefore involve the following framework:

Research proposal

↓

Scientific review

↓

Funding disclosure

↓

COI disclosure

↓

Institutional Ethics Committee

↓

Regulatory approval where required

↓

Clinical Trial Registry / applicable registration

↓

Informed consent

↓

Research

↓

Monitoring

↓

Data analysis

↓

Disclosure of funding + COI

↓

Publication

↓

Post-research accountability

The precise steps depend upon the nature of the research.

38. Key principles for examination

You can remember the subject through “D-M-A-T-P”:

D — Disclosure

Disclose funding and relevant financial/non-financial interests.

M — Management

A disclosed conflict must be managed, not merely recorded.

A — Autonomy

Researchers must retain scientific/professional independence.

T — Transparency

Participants, ethics bodies, regulators and readers should receive appropriate information.

P — Participant protection

The welfare and rights of research participants take priority over commercial interests.

39. Critical analysis

The major challenge is that research increasingly depends on private funding.

Commercial sponsorship can provide:

• expensive equipment;
• sophisticated laboratories;
• clinical-trial infrastructure;
• specialist expertise; and
• resources unavailable through public funding alone.

Therefore, banning commercial funding would not necessarily be practical or desirable.

The better approach is:

Permit funding, but regulate the relationship.

That requires:

• disclosure;
• independent ethics review;
• financial transparency;
• investigator autonomy;
• independent data analysis;
• publication rights;
• participant protection;
• monitoring; and
• sanctions for misconduct.

The Supreme Court's approach in Swasthya Adhikar Manch essentially follows this model: clinical research is necessary, but it must operate within a robust ethical and regulatory framework.

40. Conclusion

Research funding is not inherently unethical. The legal and ethical problem arises when financial sponsorship compromises—or appears capable of compromising—the independence, integrity or safety of research.

Indian law therefore increasingly follows a system of:

Disclosure + Independent Ethics Review + Conflict Management + Transparency + Participant Protection.

The ICMR National Ethical Guidelines require investigators to disclose relevant conflicts, require Ethics Committees to assess and manage those conflicts, and recognise the importance of informing participants about research sponsorship.

The Supreme Court's decision in Swasthya Adhikar Manch v. Union of India is particularly important because it recognised that payments from sponsors to investigators can act as inducements and potentially influence clinical-trial enrolment, making financial transparency an important regulatory concern.

More recently, India's National Health Research Policy 2026 expressly calls for protocols governing the identification, disclosure and management of conflicts of interest in research, review and funding decisions.

Exam-ready conclusion

In India, research funding is permissible but must be accompanied by transparency, institutional control and conflict-of-interest management. Researchers must disclose significant financial and non-financial interests to Ethics Committees and, where applicable, to research participants and scientific audiences. Ethics Committee members must themselves disclose conflicts and recuse themselves where necessary. The Supreme Court in Swasthya Adhikar Manch v. Union of India recognised the possibility that sponsor payments to investigators may create inducements capable of affecting clinical-trial conduct. Thus, Indian research governance seeks to reconcile commercial sponsorship with scientific independence, participant autonomy, public accountability and research integrity.